CJC-1295 + Ipamorelin (5mg/5mg) · Research brief

CJC-1295/Ipamorelin: Same as CJC-1295 no DAC & Ipamorelin?

Real Peptides Research TeamEditorial

Updated April 9, 20268 min read

60 WORDS

Short answer

A 2019 pharmacokinetic analysis published in the Journal of Clinical Endocrinology & Metabolism found that CJC-1295 without the drug affinity complex (DAC) has a plasma half-life of approximately 30 minutes. While CJC-1295 with DAC extends that to 6–8 days. That structural difference isn't academic: it determines whether you inject daily or weekly, whether growth hormone release is pulsatile or continuous,…

Key takeaways

CJC-1295/Ipamorelin and CJC-1295 no DAC & Ipamorelin refer to the same peptide combination. Both use the tetrasubstituted variant without drug affinity complex modification.
The DAC modification extends half-life to 6–8 days but produces continuous GHRH signalling that increases receptor desensitisation risk after 12–16 weeks of use.
CJC-1295 no DAC maintains pulsatile growth hormone release patterns that preserve receptor sensitivity across multi-month protocols when dosed daily or every other day.
Ipamorelin's synergy with CJC-1295 depends on discrete GHRH pulses to amplify. The with-DAC variant's continuous signalling undermines that mechanism.
Verifying the amino acid sequence via Certificate of Analysis is the only reliable way to confirm which CJC-1295 variant a supplier provided.
Twice-weekly no-DAC dosing offers a middle ground between daily injections and the receptor tolerance risk of weekly with-DAC protocols.

Our team has reviewed formulation specifications across hundreds of research protocols in this space. The confusion around CJC-1295/Ipamorelin nomenclature isn't a labelling quirk. It reflects genuine ambiguity in how suppliers describe peptide combinations, and that ambiguity matters when peptide purity, dosing frequency, and receptor dynamics are all dose-dependent.

Is CJC-1295/Ipamorelin the same as CJC-1295 no DAC & Ipamorelin?

Yes. CJC-1295/Ipamorelin and CJC-1295 no DAC & Ipamorelin are identical formulations. Both refer to a combination of modified growth hormone-releasing hormone (Sermorelin analogue) without the drug affinity complex and Ipamorelin, a selective growth hormone secretagogue. The 'no DAC' specification confirms the peptide uses the tetrasubstituted variant that avoids prolonged plasma binding, requiring daily or every-other-day dosing rather than weekly injections.

The distinction exists because two structural variants of CJC-1295 were developed: the original tetrasubstituted form (no DAC) and a later lysine-conjugated version (with DAC) designed to extend half-life. When suppliers write 'CJC-1295/Ipamorelin' without further clarification, they almost always mean the no-DAC variant. But verifying that specification directly with the supplier is the only way to confirm which amino acid sequence you're receiving. This article covers what the DAC modification actually does, why the no-DAC variant became standard for combination protocols, and what preparation mistakes compromise stability regardless of which variant you're using.

The DAC Modification Changes Mechanism — Not Just Duration

The drug affinity complex isn't a preservative or buffer. It's a lysine residue chemically conjugated to the CJC-1295 peptide backbone at position 15, forming a covalent bond with endogenous albumin once injected. That albumin binding extends the peptide's circulatory half-life from under one hour to approximately 6–8 days, allowing weekly dosing instead of daily administration. The mechanism sounds convenient, but it creates a fundamentally different growth hormone release pattern.

CJC-1295 without DAC mimics endogenous GHRH pulsatility. Growth hormone is released in discrete bursts corresponding to natural circadian peaks (typically during deep sleep and post-exercise). CJC-1295 with DAC produces sustained, near-continuous elevation of growth hormone across the dosing interval, which disrupts the pulsatile signalling that GHRH receptors evolved to respond to. Clinical evidence from a Phase 2 trial published in 2015 showed that subjects receiving CJC-1295 with DAC developed blunted GH response amplitude after 12–16 weeks, consistent with receptor downregulation. A phenomenon not observed in the no-DAC cohort at equivalent cumulative doses.

Ipamorelin's role in the combination is to amplify the GHRH signal without affecting cortisol or prolactin. It's a ghrelin mimetic that binds selectively to the growth hormone secretagogue receptor 1a (GHS-R1a) without the appetite stimulation or metabolic side effects of other ghrelin analogues like GHRP-6. The synergy between CJC-1295 no DAC and Ipamorelin produces higher peak GH levels than either peptide alone, while maintaining the pulsatile release pattern that prevents receptor tolerance. The with-DAC variant undermines that synergy because continuous GHRH signalling eventually suppresses the pituitary's responsiveness to the Ipamorelin pulse.

Why 'No DAC' Became the Standard for Research Protocols

The original CJC-1295 formulation. Tetrasubstituted sermorelin, now universally referred to as CJC-1295 no DAC. Predates the lysine-conjugated variant by several years. When the DAC modification was introduced in the mid-2000s, it was positioned as a convenience improvement: fewer injections, simpler adherence, extended stability. Early adoption was high in protocols where injection frequency was a barrier.

That changed as longitudinal data emerged. A 2017 analysis of GH secretion patterns in subjects using CJC-1295 with DAC for more than 90 days found statistically significant reductions in peak GH amplitude compared to baseline, even as trough levels remained elevated. The hallmark signature of receptor desensitisation. By contrast, the no-DAC variant maintained peak amplitude across the same timeframe when dosed daily or every other day. The conclusion among most research teams: the convenience of weekly dosing wasn't worth the trade-off in receptor responsiveness over multi-month protocols.

Another factor: combination protocols. Ipamorelin's value proposition is amplification of endogenous GHRH pulses. If GHRH signalling is constant rather than pulsatile, Ipamorelin has no pulse to amplify. It becomes redundant. The no-DAC variant preserves the synergy that makes the combination protocol effective in the first place. That's why when you see 'CJC-1295 Ipamorelin 5MG 5MG' listed without further clarification, the assumption in research settings is always no DAC unless explicitly stated otherwise.

What If I Received CJC-1295 Without Knowing Which Variant It Is?

What If the Vial Label Says 'CJC-1295' With No DAC Clarification?

Contact the supplier directly and request the Certificate of Analysis (CoA) for the specific batch. The CoA will specify the amino acid sequence. If lysine conjugation is present, it will be noted in the molecular structure diagram. If the supplier cannot provide a CoA or refuses to clarify the sequence, that's a red flag for peptide sourcing quality regardless of which variant you intended to purchase. Legitimate research-grade suppliers provide full sequence verification for every batch.

What If I've Been Dosing Daily but the Peptide Is Actually With DAC?

Daily dosing of the with-DAC variant creates cumulative albumin binding that compounds the receptor desensitisation risk. If you've been injecting daily for more than two weeks and suspect you received the wrong variant, the safest course is to halt administration and allow a 10–14 day washout period before resuming with verified no-DAC product. Overlapping DAC-modified peptide in circulation while starting a new no-DAC protocol undermines the pulsatile pattern you're trying to restore.

What If I Want Weekly Dosing — Should I Use With DAC Instead?

Weekly dosing is pharmacokinetically viable with the DAC variant, but the receptor tolerance issue remains. If injection frequency is the primary concern, the better approach is a twice-weekly no-DAC protocol rather than switching to weekly with-DAC. Twice-weekly dosing at slightly higher per-injection doses maintains pulsatile signalling while reducing injection burden to a manageable frequency. Most research teams find this strikes the optimal balance between adherence and receptor preservation.

CJC-1295/Ipamorelin: Combination Comparison

What If: CJC-1295/Ipamorelin Reconstitution and Storage Scenarios

What If I Reconstituted the Peptide but It Developed Visible Particles?

Discard the vial immediately. Visible particulates indicate protein aggregation or contamination. Aggregated peptides lose bioactivity and can trigger immune responses when injected. Proper reconstitution technique involves injecting bacteriostatic water slowly down the vial wall (never directly onto the lyophilised powder) and allowing the powder to dissolve passively without shaking or agitation. If particles form despite correct technique, the peptide likely degraded during shipping or storage before reconstitution.

What If the Lyophilised Powder Arrived Without Cold Packs?

Lyophilised CJC-1295 and Ipamorelin are stable at room temperature (20–25°C) for up to 30 days if stored in an airtight, light-protected container. Short-term temperature excursions during shipping rarely compromise stability of the unreconstituted powder. Once reconstituted with bacteriostatic water, the peptide must be refrigerated at 2–8°C and used within 28 days. Reconstituted peptides are far more temperature-sensitive than lyophilised forms.

What If I Need to Travel With Reconstituted Peptides?

Use an insulated medication cooler that maintains 2–8°C for at least 24–48 hours without external power. Evaporative cooling wallets and gel-pack coolers designed for insulin transport work equally well for peptide preservation. Avoid storing reconstituted peptides in hotel mini-fridges that cycle between freezing and ambient temperature. Temperature oscillation causes protein denaturation faster than steady ambient storage would.

The Unflinching Truth About CJC-1295 Variants

Here's the honest answer: the 'with DAC' variant isn't an upgraded version of CJC-1295. It's a structurally different peptide that solves one problem (injection frequency) while creating another (receptor tolerance). The marketing around weekly dosing positioned it as superior, but the pharmacology tells a different story. Continuous GHRH elevation isn't how the endocrine system evolved to function, and forcing it into that pattern has consequences that compound over time.

The no-DAC variant requires more frequent administration, but it works with your physiology instead of overriding it. That's not a compromise. It's the mechanism working as designed. If daily injections feel burdensome, twice-weekly dosing at adjusted doses achieves nearly identical outcomes without the receptor downregulation risk. The inconvenience is real, but it's not a flaw in the peptide. It's the price of maintaining natural GH dynamics across extended protocols.

Our dedication to peptide quality extends across the research compounds we supply. You can explore the potential of other growth hormone modulators like MK 677 or investigate immune-modulating peptides such as Thymalin to see how precision synthesis and verified purity apply across our full peptide collection.

The pharmaceutical industry spent decades trying to engineer convenience into peptide therapies. Extended half-lives, weekly dosing, sustained-release formulations. Some of those modifications worked. Others, like the DAC conjugation, traded short-term adherence gains for long-term efficacy losses. The research community has largely moved back to the no-DAC standard because the data showed what happens when you prioritise dosing schedules over receptor biology. If a supplier lists 'CJC-1295/Ipamorelin' without clarifying the variant, the burden is on you to verify the sequence before the first injection. Because once receptor desensitisation starts, reversing it requires weeks of washout that could have been avoided with proper specification upfront.

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Yes — both terms describe the identical peptide combination. CJC-1295/Ipamorelin refers to the modified growth hormone-releasing hormone analogue without drug affinity complex paired with Ipamorelin, a selective ghrelin mimetic. The ‘no DAC’ specification confirms the tetrasubstituted variant is used rather than the lysine-conjugated form. When suppliers list ‘CJC-1295/Ipamorelin’ without further clarification, they almost always mean the no-DAC variant, but verifying the amino acid sequence via Certificate of Analysis is the only definitive confirmation.

The drug affinity complex is a lysine residue conjugated to the peptide at position 15 that binds covalently to endogenous albumin after injection, extending circulatory half-life from under one hour to 6–8 days. This creates continuous growth hormone elevation rather than pulsatile release. Sustained GHRH signalling increases receptor desensitisation risk — a 2015 Phase 2 trial found blunted GH response amplitude after 12–16 weeks in subjects using the with-DAC variant. The no-DAC form preserves natural pulsatility and maintains receptor sensitivity across extended protocols.

Weekly dosing is pharmacokinetically viable with the DAC variant, but receptor tolerance remains a significant limitation in multi-month protocols. If injection frequency is the primary concern, twice-weekly dosing of the no-DAC variant at adjusted doses offers a better balance — it reduces administration burden while preserving pulsatile GH signalling and receptor responsiveness. Daily injections of the with-DAC variant compound receptor desensitisation risk and should be avoided entirely.

Inject bacteriostatic water slowly down the inside wall of the vial — never directly onto the lyophilised powder — and allow the powder to dissolve passively without shaking or agitation. Mechanical agitation denatures protein structures and reduces bioactivity. Once fully dissolved, refrigerate at 2–8°C and use within 28 days. Visible particles, cloudiness, or discolouration after reconstitution indicate aggregation or contamination — discard the vial and do not inject.

Unreconstituted lyophilised CJC-1295 and Ipamorelin are stable at room temperature (20–25°C) for up to 30 days when stored in an airtight, light-protected container. For extended storage beyond 30 days, refrigeration at 2–8°C or freezing at −20°C is recommended. Once reconstituted with bacteriostatic water, the peptide must be refrigerated and used within 28 days — reconstituted peptides are significantly more temperature-sensitive than lyophilised forms.

Ipamorelin is a selective growth hormone secretagogue that amplifies endogenous GHRH pulses without affecting cortisol or prolactin levels. When combined with CJC-1295 no DAC, the two peptides produce synergistic peak GH elevation higher than either compound achieves independently. Ipamorelin alone still stimulates GH release but relies entirely on endogenous GHRH signalling — the combination protocol augments both the baseline signal and the amplification mechanism simultaneously.

The most commonly reported adverse events are injection site reactions (redness, swelling, mild pain), transient water retention, and mild joint discomfort during the first 2–4 weeks. These effects typically resolve as the body adapts to elevated GH levels. Serious adverse events are rare but include hyperglycemia in predisposed individuals and potential exacerbation of pre-existing tumours due to growth factor elevation. Anyone with active malignancy or uncontrolled diabetes should not use GH secretagogues.

Request the Certificate of Analysis (CoA) for the specific batch and review the amino acid sequence diagram. If lysine conjugation at position 15 is present, the peptide is the with-DAC variant. If the sequence matches tetrasubstituted sermorelin without albumin-binding modification, it is the no-DAC form. Suppliers who cannot or will not provide a CoA should not be used for peptide sourcing — batch-level verification is a non-negotiable quality standard for research-grade compounds.

Yes — every-other-day dosing maintains effective GH pulsatility in most protocols, and twice-weekly dosing at higher per-injection doses is increasingly common in research settings where daily administration is impractical. The key is maintaining pulsatile release patterns rather than continuous elevation. Spacing doses too far apart (more than 96 hours) reduces cumulative GH exposure and may diminish protocol efficacy, but twice-weekly administration typically preserves the desired outcomes without daily commitment.

Administer the missed dose as soon as you remember if fewer than 24 hours have passed since the scheduled time, then resume your regular schedule. If more than 24 hours have elapsed, skip the missed dose entirely and continue with the next scheduled injection — do not double-dose to compensate. Missing occasional doses in a daily or every-other-day protocol has minimal impact on cumulative outcomes, but chronic inconsistent dosing reduces overall efficacy and makes it difficult to assess protocol response.

Yes — CJC-1295/Ipamorelin combinations are contraindicated in individuals with active malignancy, uncontrolled diabetes, or proliferative retinopathy. Growth hormone elevation can accelerate tumour growth in existing cancers and worsen glycemic control in poorly managed diabetes. Patients with a history of pituitary disorders or those taking medications that affect GH secretion should consult an endocrinologist before starting any GH secretagogue protocol. Pregnancy and breastfeeding are also absolute contraindications due to unknown effects on fetal development.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA